Mandate

Vinge advises Bufab in connection with the listing on NASDAQ OMX Stockholm

February 27, 2014

Vinge advises Bufab in connection with the listing on NASDAQ OMX Stockholm and Nordic Capital Fund V:s offering of shares in connection with the listing. Bufab is a trading company that delivers components and services to the global manufacturing industry. Bufab is a trading company that delivers components and services to the global manufacturing industry. The Company offers its customers a one-stop-shop product offering that covers sourcing, quality assurance and logistics of so called C-Parts, components such as nuts, screws and washers, according to the business model Supply Chain Partner. The Swedish language prospectus was published on 10 February 2014 and the first day of trading was 21 February 2014. The offering attracted strong interest among Swedish and international institutional investors as well as Swedish retail investors. The Offering was over-subscribed multiple times. The final offering price has been set at SEK 46 per share, corresponding to a market value of all shares issued by Bufab of MSEK 1,753.

Vinge’s team consisted of, among others, partners Charlotte Levin, Peter Bäärnhielm and Christina Kokko and associates Jonas Johansson, David Andersson, Mia Örnfeldt, Albert Wållgren and Rikard Lindahl.

Related

Vinge has advised Eleda in connection with Eleda Norge AS’s acquisition of Nettpartner Bane AS

Vinge, together with Advokatfirmaet Thommessen, has advised Eleda in connection with Eleda Norge AS’s acquisition of Nettpartner Bane AS from Å Energi owned Nettpartner AS.
January 19, 2026

Vinge advises KEYTO Group in connection with the acquisition of Smartify

KEYTO Group continues its growth journey by strengthening its offering in Sweden as Smartify Sverige AB joins KEYTO Group.
January 19, 2026

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026